Literature DB >> 30814253

The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain.

W Michael Babinchak1, Raza Haider1, Benjamin K Dumm1, Prottusha Sarkar1, Krystyna Surewicz1, Jin-Kyu Choi1, Witold K Surewicz2.   

Abstract

Pathological aggregation of the transactive response DNA-binding protein of 43 kDa (TDP-43) is associated with several neurodegenerative disorders, including ALS, frontotemporal dementia, chronic traumatic encephalopathy, and Alzheimer's disease. TDP-43 aggregation appears to be largely driven by its low-complexity domain (LCD), which also has a high propensity to undergo liquid-liquid phase separation (LLPS). However, the mechanism of TDP-43 LCD pathological aggregation and, most importantly, the relationship between the aggregation process and LLPS remains largely unknown. Here, we show that amyloid formation by the LCD is controlled by electrostatic repulsion. We also demonstrate that the liquid droplet environment strongly accelerates LCD fibrillation and that its aggregation under LLPS conditions involves several distinct events, culminating in rapid assembly of fibrillar aggregates that emanate from within mature liquid droplets. These combined results strongly suggest that LLPS may play a major role in pathological TDP-43 aggregation, contributing to pathogenesis in neurodegenerative diseases.
© 2019 Babinchak et al.

Entities:  

Keywords:  TAR DNA-binding protein 43 (TDP-43) (TARDBP); amyloid; amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease); fibrillation; intrinsically disordered protein; liquid-liquid phase separation; neurodegeneration; protein aggregation

Mesh:

Substances:

Year:  2019        PMID: 30814253      PMCID: PMC6484124          DOI: 10.1074/jbc.RA118.007222

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy.

Authors:  Ann C McKee; Brandon E Gavett; Robert A Stern; Christopher J Nowinski; Robert C Cantu; Neil W Kowall; Daniel P Perl; E Tessa Hedley-Whyte; Bruce Price; Chris Sullivan; Peter Morin; Hyo-Soon Lee; Caroline A Kubilus; Daniel H Daneshvar; Megan Wulff; Andrew E Budson
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

2.  A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.

Authors:  Avinash Patel; Hyun O Lee; Louise Jawerth; Shovamayee Maharana; Marcus Jahnel; Marco Y Hein; Stoyno Stoynov; Julia Mahamid; Shambaditya Saha; Titus M Franzmann; Andrej Pozniakovski; Ina Poser; Nicola Maghelli; Loic A Royer; Martin Weigert; Eugene W Myers; Stephan Grill; David Drechsel; Anthony A Hyman; Simon Alberti
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

3.  The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation.

Authors:  Peter Hortschansky; Volker Schroeckh; Tony Christopeit; Giorgia Zandomeneghi; Marcus Fändrich
Journal:  Protein Sci       Date:  2005-06-03       Impact factor: 6.725

4.  TDP-43 is a key player in the clinical features associated with Alzheimer's disease.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-03-23       Impact factor: 17.088

5.  ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor.

Authors:  Liqun Liu-Yesucevitz; Amy Y Lin; Atsushi Ebata; Joon Y Boon; Whitney Reid; Ya-Fei Xu; Kendra Kobrin; George J Murphy; Leonard Petrucelli; Benjamin Wolozin
Journal:  J Neurosci       Date:  2014-03-19       Impact factor: 6.167

Review 6.  "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS).

Authors:  Peter T Nelson; John Q Trojanowski; Erin L Abner; Omar M Al-Janabi; Gregory A Jicha; Frederick A Schmitt; Charles D Smith; David W Fardo; Wang-Xia Wang; Richard J Kryscio; Janna H Neltner; Walter A Kukull; Matthew D Cykowski; Linda J Van Eldik; Eseosa T Ighodaro
Journal:  J Neuropathol Exp Neurol       Date:  2016-05-21       Impact factor: 3.685

7.  ALS Mutations Disrupt Phase Separation Mediated by α-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain.

Authors:  Alexander E Conicella; Gül H Zerze; Jeetain Mittal; Nicolas L Fawzi
Journal:  Structure       Date:  2016-08-18       Impact factor: 5.006

8.  Updated TDP-43 in Alzheimer's disease staging scheme.

Authors:  Keith A Josephs; Melissa E Murray; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Leonard Petrucelli; Amanda M Liesinger; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2016-01-25       Impact factor: 17.088

9.  Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization.

Authors:  Leeanne McGurk; Edward Gomes; Lin Guo; Jelena Mojsilovic-Petrovic; Van Tran; Robert G Kalb; James Shorter; Nancy M Bonini
Journal:  Mol Cell       Date:  2018-08-09       Impact factor: 17.970

Review 10.  The physiological and pathological biophysics of phase separation and gelation of RNA binding proteins in amyotrophic lateral sclerosis and fronto-temporal lobar degeneration.

Authors:  Peter St George-Hyslop; Julie Qiaojin Lin; Akinori Miyashita; Emma C Phillips; Seema Qamar; Suzanne J Randle; GuoZhen Wang
Journal:  Brain Res       Date:  2018-04-30       Impact factor: 3.252

View more
  75 in total

1.  Tug of War between Condensate Phases in a Minimal Macromolecular System.

Authors:  Archishman Ghosh; Xiaojia Zhang; Huan-Xiang Zhou
Journal:  J Am Chem Soc       Date:  2020-05-04       Impact factor: 15.419

2.  Regulatory mechanisms of tau protein fibrillation under the conditions of liquid-liquid phase separation.

Authors:  Solomiia Boyko; Krystyna Surewicz; Witold K Surewicz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

Review 3.  Liquid-Liquid Phase Separation and Its Mechanistic Role in Pathological Protein Aggregation.

Authors:  W Michael Babinchak; Witold K Surewicz
Journal:  J Mol Biol       Date:  2020-03-10       Impact factor: 5.469

Review 4.  Biomolecular condensates at the nexus of cellular stress, protein aggregation disease and ageing.

Authors:  Simon Alberti; Anthony A Hyman
Journal:  Nat Rev Mol Cell Biol       Date:  2021-01-28       Impact factor: 94.444

5.  Granulins modulate liquid-liquid phase separation and aggregation of the prion-like C-terminal domain of the neurodegeneration-associated protein TDP-43.

Authors:  Anukool A Bhopatkar; Vladimir N Uversky; Vijayaraghavan Rangachari
Journal:  J Biol Chem       Date:  2020-01-06       Impact factor: 5.157

6.  Studying Protein Aggregation in the Context of Liquid-liquid Phase Separation Using Fluorescence and Atomic Force Microscopy, Fluorescence and Turbidity Assays, and FRAP.

Authors:  W Michael Babinchak; Witold K Surewicz
Journal:  Bio Protoc       Date:  2020-01-20

7.  Zinc promotes liquid-liquid phase separation of tau protein.

Authors:  Virender Singh; Ling Xu; Solomiia Boyko; Krystyna Surewicz; Witold K Surewicz
Journal:  J Biol Chem       Date:  2020-03-30       Impact factor: 5.157

Review 8.  The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.

Authors:  Heike J Wobst; Korrie L Mack; Dean G Brown; Nicholas J Brandon; James Shorter
Journal:  Med Res Rev       Date:  2020-02-11       Impact factor: 12.944

9.  Pan-retroviral Nucleocapsid-Mediated Phase Separation Regulates Genomic RNA Positioning and Trafficking.

Authors:  Anne Monette; Meijuan Niu; Lois Chen; Shringar Rao; Robert James Gorelick; Andrew John Mouland
Journal:  Cell Rep       Date:  2020-04-21       Impact factor: 9.423

10.  Tryptophan Probes of TDP-43 C-Terminal Domain Amyloid Formation.

Authors:  Sydney O Shuster; Jennifer C Lee
Journal:  J Phys Chem B       Date:  2021-04-09       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.